Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15064374 | 0.77 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL23553286 | 0.76 | CNR2 (0.66) | CNR2ALDH1A1HPGDMAPTCYP3A4 | |
| SCHEMBL11256931 | 0.75 | ALDH1A1 (0.54) | CNR2ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL7932238 | 0.75 | CTSS (0.42) | CNR2ALDH1A1CTSLCTSBCTSS | |
| SCHEMBL14399009 | 0.74 | ALDH1A1 (0.74) | CNR2ALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL25735894 | 0.74 | NLRP3 (0.72) | CNR2ALDH1A1HPGDMAPTKMT2A | |
| SCHEMBL7867488 | 0.74 | MME (0.43) | ALDH1A1MAPTCYP2C19CTSS | |
| SCHEMBL27514937 | 0.74 | CNR2 (0.59) | CNR2ALDH1A1HPGDMAPTCYP3A4 | |
| SCHEMBL15716728 | 0.73 | CTSS (0.51) | ALDH1A1MAPTKMT2ACTSLCTSB | |
| SCHEMBL14065364 | 0.73 | ALDH1A1 (0.53) | ALDH1A1CYP2C19KDM4EKMT2ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493297-B1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2493297-B1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-08-17 | — | — | EP | disclosed |
| US-8987310-B2 | Heterocycle amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987310-B2 | Heterocycle amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2493297-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120202852-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-08-09 | — | — | US | disclosed |
| US-20120202852-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-08-09 | — | — | US | disclosed |
| WO-2011053542-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011053542-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202852-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | CACNA1G, CACNA1H, CACNA1I | CNR2 155/4885ALDH1A1 3841/4885HPGD 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.